NEOS Investment Management LLC Raises Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

NEOS Investment Management LLC increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,943 shares of the biotechnology company’s stock after acquiring an additional 237 shares during the period. NEOS Investment Management LLC’s holdings in Sarepta Therapeutics were worth $236,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Sava Infond d.o.o. purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth $365,000. WINTON GROUP Ltd acquired a new stake in Sarepta Therapeutics in the 4th quarter worth about $678,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,429 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 243 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Sarepta Therapeutics by 14.7% during the 4th quarter. Prudential Financial Inc. now owns 27,965 shares of the biotechnology company’s stock valued at $3,400,000 after acquiring an additional 3,574 shares during the last quarter. Finally, Emerald Advisers LLC boosted its position in shares of Sarepta Therapeutics by 58.8% in the fourth quarter. Emerald Advisers LLC now owns 13,242 shares of the biotechnology company’s stock worth $1,610,000 after acquiring an additional 4,904 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

SRPT has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. HC Wainwright restated a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, March 19th. Royal Bank of Canada cut Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $161.00 to $87.00 in a report on Monday. Finally, Scotiabank cut their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $164.05.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $63.82 on Tuesday. Sarepta Therapeutics, Inc. has a 52 week low of $62.50 and a 52 week high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $6.19 billion, a P/E ratio of 51.06 and a beta of 0.79. The stock has a 50 day moving average of $101.57 and a 200-day moving average of $115.47.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.